L-Arginine-Dependent Nitric Oxide Production in the Blood of Patients with Type 2 Diabetes: A Pilot, Five-Year Prospective Study.

: Type 2 diabetes mellitus (T2DM) is a major cardiovascular risk factor. Nitric oxide (NO) is one of the many molecules that regulate vascular tone, and red blood cells (RBCs) are known to play an important role in adjusting cardiac function through NO export from RBCs. Our study prospectively investigated the L-arginine (L-arg)-nitric oxide (NO) metabolic pathway in the erythrocytes and plasma of subjects with T2DM.

L-arginine catabolism is driven mainly towards nitric oxide synthesis in the erythrocytes of patients with type 2 diabetes at first clinical onset.

Background: We investigated the l-arginine (l-Arg)-nitric oxide (NO) metabolic pathway in the erythrocytes (RBCs) and plasma of subjects with type 2 diabetes at first clinical onset.

Methods: RBCs and plasma were collected from 26 patients with type 2 diabetes at first clinical onset and 19 age-matched non-diabetes subjects as controls. l-Arg content was assayed by capillary electrophoresis.

Erythrocyte caspase-3 and antioxidant defense is activated in red blood cells and plasma of type 2 diabetes patients at first clinical onset.

Objectives: We studied erythrocyte (RBC) caspase-3 activity and oxidative status in plasma and RBCs of 33 patients with type 2 diabetes at first clinical onset and 23 age-matched non-diabetes control subjects.

Methods: Caspase-3 activity was assayed during the life span of RBCs; lipid peroxides and total antioxidant capacity (TEAC) were assessed in plasma and RBCs as indicators of oxidative stress and non-enzymatic antioxidant defense; and superoxide dismutase, catalase, and glutathione peroxidase activity were measured in RBCs as enzymatic antioxidants.

Results: We found that, compared to controls, RBCs caspase-3 is activated early in type 2 diabetes (P < 0.

Mortality trends in noninsulin-treated type 2 diabetes mellitus patients in the 1943-2000 period.

Aims: To investigate the major aspects of mortality in patients with noninsulin-treated type 2 diabetes mellitus (T2DM), from 1942 till 2000.

Subjects And Methods: We performed a retrospective study in 9698 noninsulin-treated T2DM patients, 5001 (51.6%) males and 4695 (48.

Meal testing and postprandial state of type 2 diabetic patients with metabolic syndrome.

Background And Aims: C reactive protein (CRP), a non-specific acute phase reactant, has been associated with multiple patogenic mechanisms involved in chronic illnesses, but up to now the significance of CRP in the postprandial state in diabetes mellitus has not been addressed.

Material And Methods: We evaluated 58 type 2 diabetic patients (33F/25 M) with associated metabolic syndrome. The main characteristics of the patients were: age 58.

NIDDM: new once-daily intervention for type 2 diabetes mellitus: Diaprel MR.

Unlabelled: Pharmacological treatment of hyperglycemia should address to both abnormalities in T2DM treatment, that is reduction of insulin resistance and restoration of normal insulin secretion. Gliclazide is a sulfonylurea compound oral hypoglycemic drug that has a unique feature of restoring the first-phase insulin secretion, which is lost in T2DM being one of the early features of disease.

Material And Method: Laboratoires Servier conducted in Romania a an open non randomized surveillance on the efficacy and safety of Diaprel MR in type 2 diabetic patients.